Top

Published in:

01-06-2012

High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer

Authors: Karina Bauer, Ulrich Nitsche, Julia Slotta-Huspenina, Enken Drecoll, Claus Hann von Weyhern, Robert Rosenberg, Heinz Höfler, Rupert Langer

Published in: Cellular Oncology | Issue 3/2012

Abstract

Background

The expression of Heat Shock Proteins (HSPs) is increased in various cancers and has been shown to correlate with biological tumor behaviour. This study aimed to investigate the impact of HSP70, HSP60 and HSP27 expression in colon cancer.

Material and methods

HSP expression was determined by immunohistochemistry on a tissue microarray with 355 primary resected colon carcinomas of all stages. Expression patterns were correlated with pathologic features (UICC pTNM category, tumor grading) and survival.

Results

Expression of HSP27, HSP60 and HSP70 ranged from negative to high. There was no correlation between HSP27, HSP60 and HSP70 expression among each other and with UICC pT category, presence of lymph node or distant metastases or tumor grading. High HSP70 expression was associated with worse overall survival (p < 0.001) and was an independent prognostic factor (p = 0.004) in multivariate analysis including the pathological parameters mentioned above. For patients without lymph node or distant metastases (UICC stages I/II) and with complete tumor excision, HSP70 expression was the only independent prognostic factor for survival (p = 0.001) and superior to UICC pT category. In left sided UICC stage I/II carcinomas, high HSP27 expression also had adverse prognostic impact and was an independent prognostic factor (p = 0.016) besides HSP70 (p = 0.002).

Conclusion

High HSP70 and HSP27 expression is associated with worse clinical outcome in colon cancer. Determination of tumoral HSP70 and HSP27 may be used as additional biomarker for risk stratification especially for UICC stage I/II patients.

Available only for authorised users

J. Ferlay, H.-R. Shin, F. Bray et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010)PubMedCrossRef

A. Jemal, R. Siegel, E. Ward et al., Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009)PubMedCrossRef

D.V.T. Catenacci, M. Kozloff, H.L. Kindler, B. Polite, Personalized Colon Cancer Care in 2010. Semin. Oncol. 38, 284–308 (2011)PubMedCrossRef

L. Sobin, M.L. Gospodarowicz, Ch Wittekind, TNM classification of malignant tumors (John Wiley & Sons, New York, 2010)

M.G. Mutch, Molecular profiling and risk stratification of adenocarcinoma of the colon. J. Surg. Oncol. 96, 693–703 (2007)PubMedCrossRef

S. Tejpar, M. Bertagnolli, F. Bosman et al., Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15, 390–404 (2010)PubMedCrossRef

S. Lindquist, E.A. Craig, The heat-shock proteins. Annu. Rev. Genet. 22, 631–677 (1988)PubMedCrossRef

S.K. Calderwood, M.A. Khaleque, D.B. Sawyer, D.R. Ciocca, Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31, 164–172 (2006)PubMedCrossRef

D.R. Ciocca, S.K. Calderwood, Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10, 86–103 (2005)PubMedCrossRef

10.

A.A. Khalil, N.F. Kabapy, S.F. Deraz, C. Smith, Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets? Biochim. Biophys. Acta 1816, 89–104 (2011)PubMed

11.

M. Sherman, G. Multhoff, Heat shock proteins in cancer. Ann. N. Y. Acad. Sci. 1113, 192–201 (2007)PubMedCrossRef

12.

F. Cappello, S. David, F. Rappa et al., The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer 5, 139 (2005)PubMedCrossRef

13.

T.S. Hwang, H.S. Han, H.K. Choi et al., Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J. Gastroenterol. Hepatol. 18, 690–700 (2003)PubMedCrossRef

14.

Y. Kanazawa, H. Isomoto, M. Oka et al., Expression of heat shock protein (Hsp) 70 and Hsp 40 in colorectal cancer. Med Oncol 20, 157–164 (2003)PubMedCrossRef

15.

X.P. Wang, G.Z. Liu, A.L. Song et al., Expression and significance of heat shock protein 70 and glucose-regulated protein 94 in human esophageal carcinoma. World J. Gastroenterol. 11, 429–432 (2005)PubMed

16.

K. Pfister, J. Radons, R. Busch et al., Patient survival by Hsp70 membrane phenotype: association with different routes of metastasis. Cancer 110, 926–935 (2007)PubMedCrossRef

17.

J. Kocsis, T. Meszaros, B. Madaras et al., High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer. Cell Stress Chaperones 16, 49–55 (2011)PubMedCrossRef

18.

A.B. Benson, D. Schrag, M.R. Somerfield et al., American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. J. Clin. Oncol. 22, 3408–3419 (2004)PubMedCrossRef

19.

J.L. Marshall, D.G. Haller, A. de Gramont et al., Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res 1, 146–154 (2007)PubMed

20.

T. Andre, A. de Gramont, An overview of adjuvant systemic chemotherapy for colon cancer. Clin. Colorectal Cancer 4(Suppl 1), S22–S28 (2004)PubMedCrossRef

21.

E.M. Tweedle, I. Khattak, C.W. Ang et al., Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut 59, 1501–1510 (2010)PubMedCrossRef

22.

A. Marx, P. Simon, R. Simon et al., AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Archiv 453, 243–248 (2008)PubMedCrossRef

23.

B. Iacopetta, Are there two sides to colorectal cancer? Int. J. Cancer 101, 403–408 (2002)PubMedCrossRef

24.

R. Langer, K. Ott, K. Specht et al., Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. Clin. Cancer Res. 14, 8279–8287 (2008)PubMedCrossRef

25.

C.S. Wong, V.W. Wong, C.M. Chan et al., Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep 20, 89–98 (2008)PubMed

26.

M. Tsuruta, H. Nishibori, H. Hasegawa et al., Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer. Oncol Rep 20, 1165–1172 (2008)PubMed

27.

D.H. Choi, J.S. Ha, W.H. Lee et al., Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett. 581, 1649–1656 (2007)PubMedCrossRef

28.

V. Dudeja, S.M. Vickers, A.K. Saluja, The role of heat shock proteins in gastrointestinal diseases. Gut 58, 1000–1009 (2009)PubMedCrossRef

29.

G. Jego, A. Hazoume, R. Seigneuric, C. Garrido, Targeting heat shock proteins in cancer. Cancer Lett (2010)

30.

Y. Fukuyo, C.R. Hunt, N. Horikoshi, Geldanamycin and its anti-cancer activities. Cancer Lett. 290, 24–35 (2010)PubMedCrossRef

31.

U. Banerji, Heat Shock Protein 90 as a Drug Target: Some Like It Hot. Clin. Cancer Res. 15, 9–14 (2009)PubMedCrossRef

32.

A. Aghdassi, P. Phillips, V. Dudeja et al., Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res. 67, 616–625 (2007)PubMedCrossRef

33.

P.A. Phillips, V. Dudeja, J.A. McCarroll et al., Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 67, 9407–9416 (2007)PubMedCrossRef

34.

Z.P. Yuan, L.J. Chen, L.Y. Fan et al., Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin. Cancer Res. 12, 3193–3199 (2006)PubMedCrossRef

Title: High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer
Authors: Karina Bauer
Ulrich Nitsche
Julia Slotta-Huspenina
Enken Drecoll
Claus Hann von Weyhern
Robert Rosenberg
Heinz Höfler
Rupert Langer
Publication date: 01-06-2012
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 3/2012
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-012-0079-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Material and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2012

Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC

MMP2 expression is a prognostic marker for primary melanoma patients

New insights and clinical advancements in cellular oncology

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma

Erratum to: The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer

An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer